Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma
| Autor: | Pierre L. Triozzi, Donn C. Young, Patricia Kinney, Joseph R. Drago, Brent C. Behrens, John J. Rinehart, Henry A. Wise |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Lung Neoplasms Fever medicine.medical_treatment Antineoplastic Agents Bone Neoplasms Gastroenterology Serine Renal cell carcinoma Internal medicine High doses Humans Medicine Receptor Carcinoma Renal Cell Fatigue Aged Chemotherapy Interferon beta Performance status business.industry Remission Induction Interferon-beta Middle Aged medicine.disease Kidney Neoplasms Recombinant Proteins Oncology Interferon Type I Toxicity Drug Evaluation Female business Interferon beta-1a Interferon beta-1b |
| Zdroj: | Journal of Clinical Oncology. 8:881-885 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1990.8.5.881 |
| Popis: | Interferon-beta-serine (IFN-beta-ser) is a muteine, recombinant IFN that is tolerated at a dose fivefold to 10-fold higher than IFN-alfa and interacts with the same cell membrane receptor as IFN-alfa. We hypothesized that at high doses IFN-beta-ser might induce a higher response rate than IFN-alfa in metastatic renal cell carcinoma. We undertook a phase II trial of IFN-beta-ser in patients with metastatic renal cell carcinoma. Patients were treated three times each week by a 2-hour intravenous infusion. Doses were escalated weekly (.25 to 5.5 mg, 1 mg = 180,000,000 U) until the maximum-tolerated treatment dose (MTTD) was determined. The MTTD is defined as one dose level less than that which caused grade 3 toxicity and was subsequently administered three times weekly for at least 4 weeks. Twenty-nine patients were entered, and 25 were assessable for response and toxicity. The performance status was 0-1 in all patients and only one patient received previous chemotherapy. The MTTD dose was 2.5 mg (range, 0.5 to 5.5 mg per treatment), although in 10 patients, doses were later deescalated because of cumulative toxicity. Initial dose-limiting toxicity and cumulative toxicity were fatigue, malaise, and fever in most patients. Hepatic transaminitis, neutropenia, and elevation of serum creatinine were also observed but were not dose-limiting. There was one complete response (CR) and four partial responses (PRs). All responses but one occurred in pulmonary metastases. The median time to response was 26 days (range, 17 to 102 days). These data demonstrate that IFN-beta-ser given in high doses exhibits significant antitumor activity in renal cell carcinoma; however, the objective response rate is 20%. This is no higher than previous IFN studies; therefore, we reject the hypothesis than IFN-beta-ser at high doses may induce a greater response rate than IFN-alfa. However, we did observe more responses than were seen in a similar trial undertaken with lower dose IFN-beta serine in renal cell carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|